Richard DeBiasio
Papers
1
Total Citations
176
H-Index
1
About
Richard DeBiasio is a pioneering figure in the field of microphysiological systems, with a primary focus on developing advanced organ-on-a-chip platforms for drug discovery and toxicity screening. His most impactful contribution is the creation of the OrganoPlate® LiverTox™, a groundbreaking 3D microfluidic liver model that enables high-throughput hepatotoxicity testing. This work, which has garnered 176 citations, represents a significant leap forward in preclinical drug safety assessment by allowing researchers to culture iPSC-derived hepatocyte aggregates in a perfused, extracellular matrix environment. DeBiasio’s innovation lies in successfully automating and validating this complex system, making it accessible for industrial-scale compound screening. His research bridges the critical gap between traditional 2D cell culture and costly animal models, offering a more physiologically relevant and scalable alternative. By integrating microfluidics with stem cell technology, DeBiasio has established a new standard for liver toxicity testing, directly impacting how pharmaceutical companies evaluate drug safety. His work continues to drive the adoption of organ-on-a-chip technology in both academic and industrial settings, positioning him as a key contributor to the future of personalized and predictive medicine.
Research Focus
Key Achievements
Top Papers
- 1